API – Commercial
| Sr. No. | Product Name | Therapeutic Category | Regulatory Status | ||
|---|---|---|---|---|---|
| Filed | Under Filing | DMF | |||
1 |
Acetazolamide | Anti-glaucoma / Diuretic |
|
||
2 |
Alogliptin Benzoate | Anti-diabetic |
|
||
3 |
Amiodarone Hydrochloride | Anti-arrhythmic |
|
|
|
4 |
Amisulpride | Anti-emetic / Anti-psychotic |
|
||
5 |
Apixaban | Anti-coagulant |
|
|
|
6 |
Azilsartan K Medoxomil | Anti-hypertensive |
|
|
|
7 |
Carbamazepine | Anti-convulsant |
|
||
8 |
Carvedilol | Anti-hypertensive |
|
||
9 |
Chlorothiazide | Diuretic |
|
||
10 |
Chlorthalidone | Anti-hypertensive |
|
||
11 |
Deferasirox | Chelating Agent |
|
|
|
12 |
Eslicarbazepine | Anti-convulsant |
|
|
|
13 |
Hydrochlorothiazide | Diuretic |
|
|
|
14 |
Irbesartan | Anti-hypertensive |
|
||
15 |
Lamotrigine | Anti-convulsant |
|
||
16 |
Lercanidipine | Anti-hypertensive |
|
|
|
17 |
Linagliptin | Anti-diabetic |
|
|
|
18 |
Mesalamine (Mesalazine) | Anti-inflammatory |
|
||
19 |
Metoprolol Succinate | Anti-hypertensive |
|
||
20 |
Metoprolol Tartrate | Anti-hypertensive |
|
||
21 |
Olmesartan Medoxomil | Anti-hypertensive |
|
|
|
22 |
Ondansetron Hydrochloride Dihydrate | Anti-emetic |
|
||
23 |
Oxcarbazepine | Anti-convulsant |
|
|
|
24 |
Oxymetazoline Hydrochloride | Topical Nasopharyngeal |
|
||
25 |
Pregabalin | Anti-convulsant |
|
||
26 |
Rosuvastatin Calcium | Anti-hyperlipoproteinemic |
|
|
|
27 |
Saxagliptin Hydrochloride Dihydrate | Anti-diabetic |
|
||
28 |
Ticagrelor | Prevention Of Thrombotic Events |
|
|
|
29 |
Xylometazoline Hydrochloride | Topical Nasopharyngeal |
|
||
USDMF
Assessed
USDMF
Filed
CEP
EDMF
NMPA
KFDA
MOG
Russia
ANVISA
Ready
DMF
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.